What the FDA labels say about taking them together
Nirmatrelvir/ritonavir and pimavanserin
Nirmatrelvir/ritonavir's FDA label of February 19, 2026 names pimavanserin in its drug interactions section; the pimavanserin label PlainMeds reads does not name nirmatrelvir/ritonavir. The nirmatrelvir/ritonavir label: “Drug Class: aripiprazole, brexpiprazole, cariprazine, iloperidone, lumateperone, pimavanserin; Drugs within Class: ↑ aripiprazole ↑ brexpiprazole ↑ cariprazine ↑ iloperidone ↑ lumateperone ↑ pimavanserin; …”
Check it at the source: the nirmatrelvir/ritonavir FDA label on DailyMed (effective February 19, 2026, Pfizer Laboratories Div Pfizer Inc); the pimavanserin FDA label on DailyMed (effective June 18, 2026, Acadia Pharmaceuticals Inc.).
What does the nirmatrelvir/ritonavir label say about pimavanserin?
Nirmatrelvir/ritonavir label, drug interactionsDrug Class: aripiprazole, brexpiprazole, cariprazine, iloperidone, lumateperone, pimavanserin; Drugs within Class: ↑ aripiprazole ↑ brexpiprazole ↑ cariprazine ↑ iloperidone ↑ lumateperone ↑ pimavanserin; Effect on Concentration: Dosage adjustment of aripiprazole, brexpiprazole, cariprazine, iloperidone, lumateperone, and pimavanserin is recommended. Refer to the individual product prescribing information for more information.
Source: FDA drug label (Paxlovid), Pfizer Laboratories Div Pfizer Inc, effective February 19, 2026 (SPL set 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a), via openFDA; the full label on DailyMed
What does the pimavanserin label say about nirmatrelvir/ritonavir?
Pimavanserin's label (effective June 18, 2026) does not name nirmatrelvir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (NUPLAZID), Acadia Pharmaceuticals Inc., effective June 18, 2026 (SPL set 1e6bea44-57d6-4bac-9328-46e1ee59f83b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nirmatrelvir/ritonavir | Pimavanserin | |
|---|---|---|
| Labeled for | COVID-19 | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $49.24 per unit 300-100 mg dose pack | $170.50 per capsule 34 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once